Is it Time to Dump BioCryst Pharmaceuticals Inc (BCRX) Stock After it Is Up 0.55% in a Week?

BioCryst Pharmaceuticals Inc (BCRX) stock has risen 0.55% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

BioCryst Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BCRX!

See Full BCRX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With BCRX Stock Today?

BioCryst Pharmaceuticals Inc (BCRX) stock is trading at $5.50 as of 9:46 AM on Wednesday, Nov 1, a gain of $0.01, or 0.09% from the previous closing price of $5.49. Volume today is light. So far 336,919 shares have traded compared to average volume of 2,900,350 shares. The stock has traded between $5.44 and $5.55 so far today.

More About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. Click Here to get the full Stock Report for BioCryst Pharmaceuticals Inc stock.